PD-1抑制剂-话题@MedSci

#PD-1抑制剂#

52篇内容 | 2939人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1278941, encodeId=9c0c12e89414d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Blood：PD-1抑制剂治疗导致成人T细胞白血病/淋巴瘤快速进展, objectType=article, longId=186025, objectId=d73e1860251e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d73e1860251e, replyNumber=0, likeNumber=70, createdTime=2020-01-11, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d73e1860251e, moduleTitle=Blood：PD-1抑制剂治疗导致成人T细胞白血病/淋巴瘤快速进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d73e1860251e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=MSD与Promega合作开发Keytruda伴侣诊断，以判断哪些患者会受益于PD-1抑制剂的治疗, objectType=article, longId=182746, objectId=ca52182e4662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca52182e4662, replyNumber=0, likeNumber=50, createdTime=2019-11-11, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca52182e4662, moduleTitle=MSD与Promega合作开发Keytruda伴侣诊断，以判断哪些患者会受益于PD-1抑制剂的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca52182e4662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278939, encodeId=183912e89399c, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=沈琳教授解读：PD-1抑制剂临“胃”不惧，突破三线治疗困局, objectType=article, longId=175682, objectId=da151e5682e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da151e5682e0, replyNumber=0, likeNumber=63, createdTime=2019-07-19, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da151e5682e0, moduleTitle=沈琳教授解读：PD-1抑制剂临“胃”不惧，突破三线治疗困局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da151e5682e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278938, encodeId=9c4412e89381c, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破, objectType=article, longId=167336, objectId=20e616e33681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e616e33681, replyNumber=0, likeNumber=66, createdTime=2019-06-02, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e616e33681, moduleTitle=新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e616e33681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278937, encodeId=c44b12e89374f, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=PD-1抑制剂治疗淋巴瘤——在探索中走向光明, objectType=article, longId=166868, objectId=4096166868b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4096166868b4, replyNumber=0, likeNumber=66, createdTime=2019-05-28, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4096166868b4, moduleTitle=PD-1抑制剂治疗淋巴瘤——在探索中走向光明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4096166868b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278936, encodeId=3b7012e893686, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Sci Adv：白血病药物联合PD-1抑制剂增强免疫治疗效果！, objectType=article, longId=161048, objectId=33fa161048ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33fa161048ff, replyNumber=0, likeNumber=66, createdTime=2019-02-26, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33fa161048ff, moduleTitle=Sci Adv：白血病药物联合PD-1抑制剂增强免疫治疗效果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33fa161048ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278935, encodeId=543212e893548, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=JAMA Oncol：一箭双雕！自身免疫标志物或可预测PD-1抑制剂的疗效和免疫相关不良事件, objectType=article, longId=159647, objectId=03c815964e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03c815964e88, replyNumber=0, likeNumber=60, createdTime=2019-02-09, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03c815964e88, moduleTitle=JAMA Oncol：一箭双雕！自身免疫标志物或可预测PD-1抑制剂的疗效和免疫相关不良事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03c815964e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278934, encodeId=5cc812e8934fa, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Lancet Haematology：重磅！中国PD-1抑制剂信迪利单抗治疗cHL关键研究荣登《柳叶刀血液病学》封面, objectType=article, longId=157428, objectId=9bed15e428fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bed15e428fb, replyNumber=0, likeNumber=89, createdTime=2019-01-08, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bed15e428fb, moduleTitle=Lancet Haematology：重磅！中国PD-1抑制剂信迪利单抗治疗cHL关键研究荣登《柳叶刀血液病学》封面, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bed15e428fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278933, encodeId=a80212e8933c6, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=PD-1抑制剂替雷利珠单抗（Tislelizumab）重拳出击，在复发/难治cHL中疗效突出, objectType=article, longId=154852, objectId=fae615485275, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fae615485275, replyNumber=0, likeNumber=80, createdTime=2018-12-02, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fae615485275, moduleTitle=PD-1抑制剂替雷利珠单抗（Tislelizumab）重拳出击，在复发/难治cHL中疗效突出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fae615485275)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期, objectType=article, longId=153166, objectId=251515316657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=251515316657, replyNumber=0, likeNumber=76, createdTime=2018-11-11, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=251515316657, moduleTitle=BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=251515316657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278931, encodeId=734112e893194, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=JCO：PD-1抑制剂治疗合并自身免疫疾病的非小细胞肺癌患者, objectType=article, longId=138067, objectId=b94913806e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94913806e3b, replyNumber=0, likeNumber=65, createdTime=2018-05-15, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94913806e3b, moduleTitle=JCO：PD-1抑制剂治疗合并自身免疫疾病的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b94913806e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278930, encodeId=bbcc12e893000, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=2018 ASCO-GI：仑伐替尼联合PD-1抑制剂治疗晚期肝内胆管癌疗效和安全性的初步研究, objectType=article, longId=127628, objectId=fb3d12e628a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb3d12e628a7, replyNumber=0, likeNumber=61, createdTime=2018-01-26, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb3d12e628a7, moduleTitle=2018 ASCO-GI：仑伐替尼联合PD-1抑制剂治疗晚期肝内胆管癌疗效和安全性的初步研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb3d12e628a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278929, encodeId=5a3312e8929eb, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=复旦肿瘤医院薛恺：理性看待PD-1抑制剂不用过于神化, objectType=article, longId=125763, objectId=6ce9125e6350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ce9125e6350, replyNumber=0, likeNumber=120, createdTime=2018-01-07, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ce9125e6350, moduleTitle=复旦肿瘤医院薛恺：理性看待PD-1抑制剂不用过于神化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ce9125e6350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278928, encodeId=69af12e8928ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Cell：效果喜人！多国科学家首次证明，溶瘤病毒联合PD-1抑制剂免疫治疗可以大幅提升癌症响应率, objectType=article, longId=114191, objectId=c583114191d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c583114191d0, replyNumber=0, likeNumber=62, createdTime=2017-09-27, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c583114191d0, moduleTitle=Cell：效果喜人！多国科学家首次证明，溶瘤病毒联合PD-1抑制剂免疫治疗可以大幅提升癌症响应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c583114191d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278927, encodeId=2b5112e8927ce, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=NEJM：“广谱抗癌药”PD-1抑制剂治疗纵隔灰区淋巴瘤有效, objectType=article, longId=105476, objectId=404d1054e621, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=404d1054e621, replyNumber=0, likeNumber=74, createdTime=2017-07-15, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=404d1054e621, moduleTitle=NEJM：“广谱抗癌药”PD-1抑制剂治疗纵隔灰区淋巴瘤有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=404d1054e621)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278926, encodeId=8b8a12e8926ae, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=JAMA Oncol：不同肿瘤和治疗方案下，PD-1抑制剂相关肺炎发生情况如何？, objectType=article, longId=77373, objectId=237ce737343, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237ce737343, replyNumber=0, likeNumber=40, createdTime=2016-09-15, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237ce737343, moduleTitle=JAMA Oncol：不同肿瘤和治疗方案下，PD-1抑制剂相关肺炎发生情况如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237ce737343)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278925, encodeId=521112e8925a0, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存, objectType=article, longId=67206, objectId=60226e206eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60226e206eb, replyNumber=0, likeNumber=82, createdTime=2016-04-28, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60226e206eb, moduleTitle=PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60226e206eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278924, encodeId=00da12e8924ad, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤, objectType=article, longId=47602, objectId=c2b04e602af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2b04e602af, replyNumber=0, likeNumber=60, createdTime=2015-03-04, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2b04e602af, moduleTitle=FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2b04e602af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278923, encodeId=539d12e892344, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时, objectType=article, longId=45436, objectId=04d8454369d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04d8454369d, replyNumber=0, likeNumber=65, createdTime=2015-01-16, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04d8454369d, moduleTitle=Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04d8454369d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278922, encodeId=621b12e892204, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=PD-1抑制剂对晚期鳞状非小细胞肺癌具有极其显著疗效，优于紫杉醇化疗, objectType=article, longId=45387, objectId=de7a4538e16, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de7a4538e16, replyNumber=0, likeNumber=53, createdTime=2015-01-14, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de7a4538e16, moduleTitle=PD-1抑制剂对晚期鳞状非小细胞肺癌具有极其显著疗效，优于紫杉醇化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de7a4538e16)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1抑制剂

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Blood：PD-1抑制剂治疗导致成人T细胞白血病/淋巴瘤快速进展

2020-01-11

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

MSD与Promega合作开发Keytruda伴侣诊断，以判断哪些患者会受益于PD-1抑制剂的治疗

2019-11-11

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

沈琳教授解读：PD-1抑制剂临“胃”不惧，突破三线治疗困局

2019-07-19

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破

2019-06-02

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

PD-1抑制剂治疗淋巴瘤——在探索中走向光明

2019-05-28

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Sci Adv：白血病药物联合PD-1抑制剂增强免疫治疗效果！

2019-02-26

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

JAMA Oncol：一箭双雕！自身免疫标志物或可预测PD-1抑制剂的疗效和免疫相关不良事件

2019-02-09

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Lancet Haematology：重磅！中国PD-1抑制剂信迪利单抗治疗cHL关键研究荣登《柳叶刀血液病学》封面

2019-01-08

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

PD-1抑制剂替雷利珠单抗（Tislelizumab）重拳出击，在复发/难治cHL中疗效突出

2018-12-02

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期

2018-11-11

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

JCO：PD-1抑制剂治疗合并自身免疫疾病的非小细胞肺癌患者

2018-05-15

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

2018 ASCO-GI：仑伐替尼联合PD-1抑制剂治疗晚期肝内胆管癌疗效和安全性的初步研究

2018-01-26

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

复旦肿瘤医院薛恺：理性看待PD-1抑制剂不用过于神化

2018-01-07

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Cell：效果喜人！多国科学家首次证明，溶瘤病毒联合PD-1抑制剂免疫治疗可以大幅提升癌症响应率

2017-09-27

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

NEJM：“广谱抗癌药”PD-1抑制剂治疗纵隔灰区淋巴瘤有效

2017-07-15

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

JAMA Oncol：不同肿瘤和治疗方案下，PD-1抑制剂相关肺炎发生情况如何？

2016-09-15

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存

2016-04-28

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤

2015-03-04

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时

2015-01-16

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

PD-1抑制剂对晚期鳞状非小细胞肺癌具有极其显著疗效，优于紫杉醇化疗

2015-01-14

科室
- - 订阅+
  - 更多科室
工具
服务